This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 1 of 1 for:    SYR-322-_106
Previous Study | Return to List | Next Study

Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: July 8, 2011
Last updated: February 17, 2013
Last verified: February 2013
The purpose of this study is to assess the Pharmacokinetics and Pharmacodynamics of alogliptin after a single or multiple administrations, once daily (QD), of oral alogliptin in healthy Korean subjects.

Condition Intervention Phase
Pharmacokinetics and Pharmacodynamics Drug: Alogliptin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple-Dose Study of the Pharmacokinetics and Pharmacodynamics of Alogliptin 12.5 mg, 25 mg and 50 mg in Healthy Korean Subjects

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Cmax: Maximum Observed Plasma Concentration Pharmacokinetic Parameter [ Time Frame: Day 1-4, Day 10 ]
    Maximum observed plasma concentration (Cmax) is the peak plasma concentration after administrations of a single dose and multiple doses of the study drug

  • Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) Pharmacokinetic Parameter [ Time Frame: Day 1-4, Day 10. ]
    Time to reach the maximum plasma concentration (Tmax) after administrations of a single dose and multiple doses of the study drug

  • AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity Pharmacokinetic Parameter [ Time Frame: Day 1-4 ]
    Area under the plasma concentration-time curve from time 0 to infinity after administration of a single dose of the study drug.

  • AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Pharmacokinetic Parameter. [ Time Frame: Day 1-4, Day 10. ]
    Area under the curve from 0 to 24 hours after administrations of a single dose and multiple doses of the study drug.

  • Terminal Phase Elimination Half-life (T1/2) Pharmacokinetic Parameter [ Time Frame: Day 1-4 ]
    Time required for half of the drug to be eliminated from the plasma after administration of a single dose of the study drug.

  • Oral Clearance (CL/F) Pharmacokinetic Parameter [ Time Frame: Day 1-4 ]
    CL/F is apparent clearance of the drug from the plasma after administration of a single dose of the study drug.

Enrollment: 48
Study Start Date: July 2011
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alogliptin 12.5 mg QD Drug: Alogliptin
Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
Other Name: SYR-322
Experimental: Alogliptin 25 mg QD Drug: Alogliptin
Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
Other Name: SYR-322
Experimental: Alogliptin 50 mg QD Drug: Alogliptin
Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
Other Name: SYR-322

Detailed Description:

Alogliptin is a selective, orally available inhibitor of dipeptidyl peptidase-4 being developed by Takeda Global Research & Development Center, Inc. as a treatment for type 2 diabetes mellitus. Inhibition of dipeptidyl peptidase-4 (DPP-4) prolongs the action of 2 important incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones are responsible for increasing insulin synthesis, regulating β-cell proliferation, inhibiting gastric emptying and inhibiting glucagon secretion.

Evaluations of alogliptin and its clinical efficacy have been conducted in multiple countries including the United States and Japan. As development of alogliptin expands to other countries, additional studies are needed to bridge between the data previously acquired.

The main objective of this study is to assess the pharmacokinetics and pharmacodynamics of alogliptin in healthy Korean participants.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is a healthy adult male or female participant of Korean descent.
  4. The participant is aged 18 to 55 years, inclusive, at the time of informed consent and first study medication dose.
  5. The participant has a body mass index (BMI) between 18.0 and 26.0 kg/m2, inclusive at Screening.
  6. A male participant who is non-sterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 12 weeks after last the dose.
  7. A female participant of childbearing potential who is sexually active with a non-sterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after the last dose of study drug.

Exclusion Criteria:

  1. The participant has received any investigational compound within 30 days prior to Screening.
  2. The participant has received alogliptin in a previous clinical study or as a therapeutic agent.
  3. The participant is an immediate family member, study site employee, or in a dependant relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  4. The participant has history of uncontrolled, clinically significant manifestations of metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), endocrine, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, rheumatologic, skin and subcutaneous tissue disorders, infectious, hepatic, renal, urologic, immunologic, psychiatric or mood disorders (including any past history of suicide attempt), or a history of lactose intolerance, which may impact the ability of the participant to participate or potentially confound the study results.
  5. Participant has a known hypersensitivity to any component of the formulation of alogliptin.
  6. The participant has a positive urine drug result for drugs of abuse or alcohol at Screening or Check-in (Day -1).
  7. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study.
  8. Participant has taken any excluded medication, supplements, or food products listed in the Excluded Medications and Dietary Products table.
  9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after participating in this study; or intending to donate ova during such time period.
  10. If male, the participant intends to donate sperm during the course of this study or for 12 weeks after the last dose.
  11. Participant has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory tests giving reasonable suspicion of a disease that would contraindicate taking alogliptin, or a similar drug in the same class, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias.
  12. Participant has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (i.e., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis frequent [more than once per week] occurrence of heartburn, or any surgical intervention [e.g., cholecystectomy]).
  13. Participant has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
  14. Participant has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), or a known history of human immunodeficiency virus infection at the Screening visit.
  15. Participant has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in Day -1. Cotinine test is positive at Screening or Check-in (Day -1).
  16. The participant has poor peripheral venous access.
  17. Participant has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day 1.
  18. Participant has a Screening or Check-in (Day -1) abnormal (clinically significant) electrocardiogram (ECG). Entry of any participant with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator.
  19. Participant has abnormal Screening or Day -1 laboratory values that suggest a clinically significant underlying disease or participant with the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >2x the upper limits of normal.
  20. Participant has a hemoglobin value <12 g/dL at Screening only.
  21. Participant has a systolic blood pressure ≥140 mm Hg or has a diastolic blood pressure ≥90 mm Hg at Screening or Check-in (Day -1).
  22. Participant has a serum creatinine level >1.5 mg/dL at Screening only.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01391663

Korea, Republic of
Seoul, Korea, Republic of
Sponsors and Collaborators
Study Director: Clinical Director Clinical Science Takeda
  More Information

Responsible Party: Takeda Identifier: NCT01391663     History of Changes
Other Study ID Numbers: SYR-322_106
U1111-1121-7268 ( Registry Identifier: WHO )
Study First Received: July 8, 2011
Results First Received: October 29, 2012
Last Updated: February 17, 2013

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017